Approval Details and Product Status

On February 19, 2015, the U.S. Food and Drug Administration (FDA) approved Actavis Elizabeth LLC's buprenorphine hydrochloride 2mg/8mg sublingual tablets under ANDA 090819. This product is a generic version of the brand-name drug Subutex and received an AB therapeutic equivalence code in the FDA's Orange Book. It is a marketed prescription drug, not in the development stage, and is distributed under the name Actavis Pharma, Inc. Actavis' generic business was acquired by Teva Pharmaceutical Industries Ltd. (TEVA) in 2016, so its current economic context is linked to Teva's U.S. generic portfolio.

Mechanism of Action and Patient Implications

Buprenorphine is a partial agonist at the μ-opioid receptor and an antagonist at the κ-opioid receptor, making it a primary component in the induction treatment of opioid dependence. While it has a ceiling effect on opioid effects and respiratory depression compared to full agonists like methadone, it is a Schedule III controlled substance, and the risks of misuse, dependence, and withdrawal must be managed. The single-ingredient sublingual tablet is selected in clinically appropriate patient populations, such as those who are pregnant, as opposed to Suboxone, which contains naloxone. This selection is contingent upon comprehensive treatment, including counseling and behavioral therapy. In 2022, the FDA updated the labeling for transmucosal buprenorphine products to reflect the risk of dental caries and QT prolongation.

Regulatory History and Competitive Landscape

The original Subutex was approved by the FDA on October 8, 2002. The Actavis product is an ANDA generic approval based on bioequivalence to the original, rather than an NDA requiring separate efficacy trials. Therefore, the key aspect of this regulatory event is the completion of quality and equivalence review for the 2mg/8mg formulation, rather than Phase 1, 2, or 3 clinical trials or an advisory committee (AdComm) vote. Direct competitors include buprenorphine sublingual generics from Hikma Pharmaceuticals (HIK), Sun Pharmaceutical Industries, and Rhodes Pharmaceuticals. In terms of treatment options, Suboxone and Zubsolv sublingual tablets, Sublocade and Brixadi long-acting injectables, methadone, and naltrexone (Vivitrol) are also competitors.

Market and Investment Implications

The global market for opioid use disorder (OUD) treatments was USD 6.0 billion in 2025, and buprenorphine-based products accounted for 59.58% of this market in the same year. In the U.S., buprenorphine prescriptions exceeded 15 million in 2024, demonstrating its role as a widely accessible maintenance treatment. However, due to the presence of multiple AB-rated generics competing on price, the profitability of the Actavis sublingual tablet itself is lower than that of long-acting, proprietary products. The fact that Indivior (INDV)'s monthly injectable, Sublocade, generated USD 1.2 billion in revenue in 2025 demonstrates that the market value is shifting from low-cost oral medications to long-acting formulations that improve adherence. Therefore, the strategic value of this generic lies in maintaining a prescription base and ensuring a stable supply, rather than in high growth potential.